BEONE MEDICINES LTD (ONC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$358.26-1.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ONC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 39.3% |
| Our one-year growth estimate | diamond | 20.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ONC — director transition
Dated 2026-06-11
Director — Michael Goller, Ranjeev Krishana, Corazon (Corsee) D. Sanders, Qingqing Yi: The directors did not stand for re-election at the Annual Meeting.
Why it matters: Reaching this income level shows strong financial health and good operations. It helps with future investments.
Supportive ifGAAP operating income reaches or exceeds $1 billion in 2026.
Worry ifGAAP operating income remains below $1 billion for the year.
Why it matters: FDA decisions on sonrotoclax are key for BeOne's growth in blood cancer treatment. Approval can help them gain more market share.
Supportive ifThe FDA has approved sonrotoclax. It is a treatment for relapsed or refractory mantle cell lymphoma.
Worry ifFDA denies approval or delays action on sonrotoclax beyond 1H 2026.
Why it matters: Expanding BRUKINSA's market presence is key for revenue growth. This will impact future earnings.
Supportive ifBRUKINSA announced new markets. This is expected to increase revenue.
Worry ifThere are no new market announcements or delays in expansion plans.
Why it matters: Operating income growth is crucial for reaching the $750-$850M target. This reflects overall business health.
Supportive ifOperating income was over $300M for Q2.
Worry ifOperating income was under $200M for Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$139 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $369 loss on $10,000 · 3.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,105 loss on $10,000 · 31.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Growing BRUKINSA sales is important for BeOne's market growth. Good sales help the growth plan.
Supportive ifBRUKINSA global revenues increase year over year by more than 30%.
Worry ifBRUKINSA global revenues grow year over year by less than 20%.
Why it matters: Good trial results could show sonrotoclax works well and help its market position.
Watch forSonrotoclax works well in the CELESTIAL-RRMCL trial.
Also watch forSonrotoclax fails to meet primary endpoints in the CELESTIAL-RRMCL trial.
Why it matters: Good results from the trial could strengthen sonrotoclax's market position and sales.
Watch forThe trial shows sonrotoclax helps a lot in treating relapsed or refractory MCL.
Also watch forThe trial does not show any benefit for sonrotoclax.
Why it matters: New data may boost confidence in sonrotoclax as a top treatment for CLL.
Watch forPositive trial results for sonrotoclax in CLL will be shared at ASCO 2026.
Also watch forNegative trial results or no new data presented at ASCO 2026.
Why it matters: Progress in sonrotoclax trials is key for BeOne's growth. Good news could raise investor trust.
Watch forGood interim results came from sonrotoclax Phase 3 trials.
Also watch forBad interim results came from sonrotoclax Phase 3 trials.
Why it matters: A good FDA decision would improve BeOne's cancer treatment options and market reach.
Supportive ifFDA approves TEVIMBRA's sBLA for first-line HER2-positive GEA treatment.
Worry ifFDA rejects TEVIMBRA's sBLA for first-line HER2-positive GEA treatment.
Why it matters: Strong sales growth would confirm BEQALZI's market acceptance as a new treatment option for MCL.
Supportive ifBEQALZI sales exceed $100 million in Q2 2026.
Worry ifBEQALZI sales fall below $50 million in Q2 2026.
Why it matters: Maintaining a high gross margin is crucial for profitability. It reflects cost management and product mix success.
Supportive ifGAAP gross margin remains above 85% for Q3.
Worry ifGAAP gross margin falls below 85% for Q3.
Why it matters: FDA approval for BEQALZI could improve BeOne's products and income. This is an important step.
Supportive ifThe FDA has approved BEQALZI. It is for treating relapsed or refractory MCL.
Worry ifFDA denies approval for BEQALZI or delays action beyond H1 2026.
Why it matters: Strong growth in operating income shows good cost control and revenue. It shows the company's health.
Supportive ifGAAP operating income for Q3 is at least $325 million.
Worry ifGAAP operating income for Q3 falls below $250 million.